ReviewScientifica2013
Melanoma: from melanocyte to genetic alterations and clinical options.
Review in Scientifica, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 1 synthesis or guideline pooled it, 125 citations in OpenAlex.
- Machine learning in the prediction of immunotherapy response and prognosis of melanoma: a systematic review and meta-analysis.Frontiers in immunology · 2024Pooled it
- Translating Features to Findings: Deep Learning for Melanoma Subtype Prediction.Dermatopathology (Basel, Switzerland) · 2025Review
- Article
- Article
- Ibrutinib Modulates Proliferation, Migration, Mitochondrial Homeostasis, and Apoptosis in Melanoma Cells.Biomedicines · 2024Article
- Targeted DNA Methylation Editing Using an All-in-One System Establishes Paradoxical Activation ofCancers · 2024Article
- Differential Gene Expression and Tumorigenicity Analysis of Cultured Melanocyte Comparing Melanoma.International journal of molecular and cellular medicine · 2024Article
- Article
- In Vitro Interaction of Melanoma-Derived Extracellular Vesicles with Collagen.International journal of molecular sciences · 2023Article
- Advances in the roles of glycyrrhizic acid in cancer therapy.Frontiers in pharmacology · 2023Review
- The Potential of Antibody Technology and Silver Nanoparticles for Enhancing Photodynamic Therapy for Melanoma.Biomedicines · 2022Review
- PFKFB4 interacts with ICMT and activates RAS/AKT signaling-dependent cell migration in melanoma.Life science alliance · 2022Article
- Exosome application in tumorigenesis: diagnosis and treatment of melanoma.Medical oncology (Northwood, London, England) · 2022Review
- The Dark Side of Melanin Secretion in Cutaneous Melanoma Aggressiveness.Frontiers in oncology · 2022Review
- Melanization as unfavorable factor in amelanotic melanoma cell biology.Protoplasma · 2021Article
- Skin Cancers and the Contribution of Rho GTPase Signaling Networks to Their Progression.Cancers · 2021Review
- UVB Radiation and Selected Tryptophan-Derived AhR Ligands-Potential Biological Interactions in Melanoma Cells.International journal of molecular sciences · 2021Article
- Unbiased High-Throughput Drug Combination Pilot Screening Identifies Synergistic Drug Combinations Effective against Patient-Derived and Drug-Resistant Melanoma Cell Lines.SLAS discovery : advancing life sciences R & D · 2021Article
- Network models of primary melanoma microenvironments identify key melanoma regulators underlying prognosis.Nature communications · 2021Article
- Identification of Therapeutic Targets and Prognostic Biomarkers Among Integrin Subunits in the Skin Cutaneous Melanoma Microenvironment.Frontiers in oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metastatic melanoma remained for decades without any effective treatment and was thus considered as a paradigm of cancer resistance. Recent progress with understanding of the molecular mechanisms underlying melanoma initiation and progression revealed that melanomas are genetically and phenotypically heterogeneous tumors. This recent progress has allowed for the development of treatment able to improve for the first time the overall disease-free survival of metastatic melanoma patients. However, clinical responses are still either too transient or limited to restricted patient subsets. The complete cure of metastatic melanoma therefore remains a challenge in the clinic. This review aims to present the recent knowledge and discoveries of the molecular mechanisms involved in melanoma pathogenesis and their exploitation into clinic that have recently facilitated bench to bedside advances.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.